Cargando…

Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study

PURPOSE: Development of innovative drugs for melanoma is occurring rapidly. Incremental gains in overall survival amongst innovative products may be difficult to measure in clinical trials, and their use may be associated with increased toxicity profiles. Therefore, HTA agencies increasingly require...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makady, Amr, Kalf, Rachel R. J., Ryll, Bettina, Spurrier, Gilliosa, de Boer, Anthonius, Hillege, Hans, Klungel, Olaf H., Goettsch, Wim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267816/ https://www.ncbi.nlm.nih.gov/pubmed/30497502 http://dx.doi.org/10.1186/s12955-018-1047-z

Ejemplares similares

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

Use of Social Media in the Assessment of Relative Effectiveness: Explorative Review With Examples From Oncology
por: Kalf, Rachel RJ, et al.
Publicado: (2018)

Information Patients With Melanoma Spontaneously Report About Health-Related Quality of Life on Web-Based Forums: Case Study
por: Kalf, Rachel R J, et al.
Publicado: (2021)

Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia
por: Wasir, Riswandy, et al.
Publicado: (2019)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases
por: Annemans, Lieven, et al.
Publicado: (2020)

Gastrointestinal toxicity among patients taking selective COX‐2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case–control study
por: Bakhriansyah, Mohammad, et al.
Publicado: (2017)

Risk of myocardial infarction associated with non‐steroidal anti‐inflammatory drugs: Impact of additional confounding control for variables collected from self‐reported data
por: Bakhriansyah, Mohammad, et al.
Publicado: (2019)

Defining the noninferiority margin and analysing noninferiority: An overview
por: Althunian, Turki A., et al.
Publicado: (2017)

Quality of reporting of drug exposure in pharmacoepidemiological studies
por: Hempenius, Mirjam, et al.
Publicado: (2020)

Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions
por: Hempenius, Mirjam, et al.
Publicado: (2019)

Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact
por: Hempenius, Mirjam, et al.
Publicado: (2021)

Patterns of antiplatelet drug use after a first myocardial infarction during a 10‐year period
por: Yasmina, Alfi, et al.
Publicado: (2016)

Cyclo‐oxygenase selectivity and chemical groups of nonsteroidal anti‐inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in VigiBase
por: Bakhriansyah, Mohammad, et al.
Publicado: (2019)

Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision‐making of oncology medicines
por: Kalf, Rachel R. J., et al.
Publicado: (2021)

Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case–control study
por: Bakhriansyah, Mohammad, et al.
Publicado: (2019)

Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review
por: Althunian, Turki A., et al.
Publicado: (2017)

Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants
por: Hempenius, Mirjam, et al.
Publicado: (2021)

The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries
por: Kleijnen, Sarah, et al.
Publicado: (2017)

Pharmacogenomic insights into treatment and management of statin-induced myopathy
por: Peters, Bas JM, et al.
Publicado: (2009)

Room for Improvement in Conducting and Reporting Non-Inferiority Randomized Controlled Trials on Drugs: A Systematic Review
por: Wangge, Grace, et al.
Publicado: (2010)

Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study
por: Hempenius, Mirjam, et al.
Publicado: (2022)

Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study
por: Althunian, Turki A., et al.
Publicado: (2020)

Patient value: Perspectives from the advocacy community
por: Addario, Bonnie J, et al.
Publicado: (2017)

Digitale Gesundheitsanwendungen (DiGA): Patientenzentrierte Gesundheitsversorgung mit disruptivem Potenzial
por: Ryll, Bettina
Publicado: (2021)

Good practices for real‐world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR‐ISPE Special Task Force on real‐world evidence in health care decision making
por: Berger, Marc L., et al.
Publicado: (2017)

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
por: Vreman, Rick A., et al.
Publicado: (2020)

Ten (not so) simple rules for clinical trial data-sharing
por: Pellen, Claude, et al.
Publicado: (2023)

Phase IV non-inferiority trials and additional claims of benefit
por: Bernabe, Rosemarie DLC, et al.
Publicado: (2013)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis
por: A Vreman, Rick, et al.
Publicado: (2020)

Clinically feasible semi-automatic workflows for measuring metabolically active tumour volume in metastatic melanoma
por: van Sluis, Joyce, et al.
Publicado: (2020)

Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE)
por: Lai-Kwon, Julia, et al.
Publicado: (2022)

Imaging of metastatic melanoma
por: Michael King, D
Publicado: (2006)

Metastatic melanoma to the testis
por: Patnana, Madhavi, et al.
Publicado: (2018)

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Development of an eHealth-enhanced model of care for the monitoring and management of immune-related adverse events in patients treated with immune checkpoint inhibitors
por: da Silva Lopes, André Manuel, et al.
Publicado: (2023)

Metastatic malignant melanoma of unknown primary in temporalis muscle
por: Grech, Alexia, et al.
Publicado: (2020)

Targeted and Checkpoint Inhibitor Therapy of Metastatic Malignant Melanoma in Germany, 2000–2016
por: Hellmund, Peter, et al.
Publicado: (2020)

Personalized medicine in Europe: not yet personal enough?
por: Di Paolo, Antonello, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ipbnaifeub5ku04pgt2p7rp9i3